Application Note

Natural Killer Cells Manufacturing

Source: Cytiva

Many studies are evaluating natural killer (NK) cells as potential cancer treatments. However, it is challenging to obtain primary human NK cells at clinically relevant scale. Here, we generated 1 × 109 cells in a workflow amenable to a current good manufacturing practices (cGMP) environment.

Learn the workflow for xeno‑free natural killer cell expansion from leukapheresis units. The process incorporates several automated and functionally closed unit operations. Overall, the methodology presented here is compatible with industrial workflows for natural killer cell manufacturing. Follow the feasibility of xeno‑free NK cell expansion, closure of key unit operations, and how future work could focus on fine‑tuning each step to generate a robust, scalable process.

access the Application Note!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Biosimilar Development